Unfortunately, I think it’ll be a buyout by Novartis based on CHF results.... pipeline can be expanded across many inflammatory indications with all the lab work done and set in a too low share price... but this changes if ARDS reads out as OE....which could happen any day... kind of a Schroedinger’s cat situation hanging like the sword of Damocles that, if OE on ARDS, would make this potential major Novartis division MUCH more expensive....and they’ve kicked the tires enough with their ARDS deal with MESO to know what they’d be getting...
I say unfortunate, as I think we’d get a lot more value over long term if stayed independent
JMHO
Unfortunately, I think it’ll be a buyout by Novartis based on...
-
- There are more pages in this discussion • 183 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29390 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 14089 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |